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RegulatoryThe mouse dose at the lowest water concentration used in the National Toxicology Program hexavalent
chromium (CrVI) drinking water study (NTP, 2008) is about 74,500 times higher than the approximate
human dose corresponding to the 35-city geometric mean reported in EWG (2010) and over 1000 times
higher than that based on the highest reported tap water concentration. With experimental and
environmental doses differing greatly, it is a regulatory challenge to extrapolate high-dose results to
environmental doses orders of magnitude lower in a meaningful and toxicologically predictive manner.
This seems particularly true for the low-dose extrapolation of results for oral CrVI-induced carcinogenesis
since dose-dependent differences in the dose fraction absorbed by mouse target tissues are apparent
(Kirman et al., 2012). These data can be used for a straightforward adjustment of the USEPA (2010) draft
oral slope factor (SFo) to be more predictive of risk at environmentally-relevant doses. More speciﬁcally,
the evaluation of observed and modeled differences in the fraction of dose absorbed by target tissues at
the point-of-departure for the draft SFo calculation versus lower doses suggests that the draft SFo be
divided by a dose-speciﬁc adjustment factor of at least an order of magnitude to be less over-predictive
of risk at more environmentally-relevant doses.
 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In recent years, there has been a great deal of scientiﬁc debate
and new research regarding exactly how and under what condi-
tions CrVI is likely to induce cancer following oral exposure
(e.g., Thompson et al., 2011a; McCarroll et al., 2010; USEPA,
2010). Some signiﬁcant topics of debate concern issues relevant
to the mode of action (MOA) and whether the excess risk
observed at very high mouse oral doses of CrVI would be
expected to extrapolate downward to signiﬁcantly lower, truly
environmentally-relevant human doses in a linear manner or if
a nonlinear/threshold dose–response should be expected at such
low doses. Such topics include the roles of mutagenicity and
chronic hyperplasia in CrVI-induced carcinogenicity in target
tissues, if the MOA and/or gastrointestinal (GI) extracellular
reductive capacity likely impart a nonlinear/threshold character
to the dose–response, and the potential that mouse oral doses
in NTP (2008) exceeded the extracellular CrVI reductive capacity
of the stomach/GI tract.
As part of the CrVI MOA research project (e.g., Thompson et al.,
2011a), Proctor et al. (2012) report that stomach reducing capacity
was likely exceeded at doses causing cancer in the mouse smallintestine, and indicate that physiologically-based toxicokinetic
(PBTK) models are necessary to account for competing kinetic rates
in extrapolating target tissue dose for the purpose of risk assess-
ment. If extracellular CrVI reductive capacity is exceeded at high
drinking water concentrations such as those inducing cancer of
the small intestine in NTP (2008), increased tissue uptake would
be anticipated compared to lower doses (Thompson et al.,
2011b). In other words, dose-dependent changes in the fraction
of dose absorbed would be expected at doses which exceed stom-
ach/GI extracellular CrVI reductive capacity compared to those that
do not, with a higher dose fraction absorbed at doses exceeding
reductive capacity.
In this study, tissue concentration data collected at various
doses as part of the CrVI MOA research project (including some
doses lower than those used in NTP, 2008) are evaluated to:
(1) quantify differences in the dose fraction absorbed at relevant
doses; and
(2) derive factors based on dose-dependent changes in target
tissue absorption that may be used to adjust the draft oral
slope factor (SFo) to be more predictive of risk at lower,
more environmentally-relevant doses.
Table 1
Total chromium target tissue concentrations in B6C3F1 mice.a
Drinking water
concentration
(mg SDD/L)
Dose
(mg Cr/
kg-
day)
Body
weightb
(g)
Total daily
dosec (mg
Cr/day)
Duodenum tissue
concentration
(mean mg Cr/kg
tissue)
±SD 95% UCLd
(mg Cr/kg
tissue)
95% LCLe
(mg Cr/kg
tissue)
Jejunum tissue
concentration
(mean mg Cr/kg
tissue)
±SD 95% UCL
(mg Cr/
kg tissue)
95% LCL
(mg Cr/
kg tissue)
Ileum tissue
concentration
(mean mg Cr/kg
tissue)
±SD 95% UCL
(mg Cr/
kg tissue)
95% LCL
(mg Cr/
kg tissue)
0 0 25.8 0 0.017 0.007 0.022 0.012 0.046 0.044 0.078 0.014 0.020 0.01 0.027 0.013
0.3f 0.024 26.4 0.001 0.056 0.015 0.067 0.045 0.034 0.021 0.049 0.019 0.014 0.000 0.014 0.014
4 0.32 25.9 0.008 1.5 0.27 1.7 1.3 0.11 0.052 0.15 0.07 0.042 0.03 0.066 0.018
14 1.1 26.3 0.029 7.3 0.78 7.9 6.7 0.33 0.29 0.54 0.12 0.13 0.03 0.15 0.11
60 4.6 25.3 0.116 33.5 5.0 37.2 29.8 4.7 3.3 7.1 2.3 0.92 1.0 1.66 0.18
170 11.6 24.9 0.289 42.4 12.4 51.5 33.3 21.6 14.8 32.5 10.7 1.8 1.1 2.6 1.0
520 30.9 23.3 0.720 60.9 14.1 71.3 50.5 13.9 6.9 19.0 8.8 2.3 0.86 2.9 1.7
a Drinking water and tissue data taken from Table 3 of Kirman et al. (2012), who reported bold italicized values as signiﬁcantly different than controls (p < 0.05).
b Body weight data from Table S2 of Thompson et al. (2011b).
c Calculated as mg Cr/kg-day  body weight in kilograms.
d 95%UCL = mean + (1.645  SE) where SE = SD/n^0.5 and n = 5.
e 95%LCL = mean  (1.645  SE) where SE = SD/n^0.5 and n = 5.
f Corresponds to the federal MCL of 0.1 mg Cr/L; MW of Cr2/MW of SDD  104/298  0.35 as conversion factor to convert SDD concentrations to Cr.
Table 2
Added chromium target tissue concentrations in B6C3F1 mice.a
Drinking
water dose
(mg Cr/kg-
day)
Body
weightb(g)
Total
daily
dosec (mg
Cr/day)
Duodenum tissue
concentration (mean
added mg Cr/kg
tissue)
±SD 95% UCLd
(added mg
Cr/kg
tissue)
95% LCLe
(added mg
Cr/kg
tissue)
Jejunum tissue
concentration
(mean added mg Cr/
kg tissue)
±SD 95% UCL
(added mg
Cr/kg
tissue)
95% LCL
(added mg
Cr/kg
tissue)
Ileum tissue
concentration
(mean added mg
Cr/kg tissue)
±SD 95% UCL
(added mg
Cr/kg
tissue)
95% LCL
(added mg
Cr/kg
tissue)
0.024 26.4 0.001 0.039 0.015 0.050 0.028 0 0.021 0 0 0 0.000 0 0
0.32 25.9 0.008 1.5 0.3 1.7 1.3 0.068 0.052 5.78E05 1.62E05 0.021 0.033 0.045 0.003
1.1 26.3 0.029 7.2 0.8 7.8 6.6 0.28 0.29 2.72E04 3.68E05 0.11 0.03 0.13 0.09
4.6 25.3 0.116 33.5 5.0 37.2 29.8 4.7 3.3 3.79E03 1.21E03 0.9 1.0 1.6 0.16
11.6 24.9 0.289 42.4 12.4 51.5 33.3 21.5 14.8 1.69E02 5.55E03 1.8 1.1 2.6 1.0
30.9 23.3 0.720 60.9 14.1 71.3 50.5 13.8 6.9 9.24E03 4.27E03 2.3 0.9 3.0 1.6
a Drinking water doses and added Cr (over background) tissue data taken from Table 8 of Kirman et al. (2012) with background shown as zero added.
b Body weight data from Table S2 of Thompson et al. (2011b).
c Calculated as mg Cr/kg-day  body weight in kilograms.
d 95%UCL = mean + (1.645  SE) where SE = SD/n^0.5 and n = 5.
e 95%LCL = mean  (1.645  SE) where SE = SD/n^0.5 and n = 5.
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Table 3
Absorbed dose fraction estimates for the mouse duodenum.
Drinking Water 
Concentration Dosea
Total Daily 
Dose
Duodenum 
Weightc
Duodenum 
Total Crd
95% UCL 
Duodenum 
Total Cr
95% LCL 
Duodenum 
Total Cr 
(mg SDD/L)  (mg Cr/kg-
day)
 (mg Cr/day) (kg) (mg) (mg) (mg)
0 0 0 0.012 3.10E-04 5.26E-06 6.86E-06 3.67E-06
0.3 f 0.024 0.001 0.012 3.17E-04 1.77E-05 2.12E-05 1.42E-05 1.97E-02 2.27E-02 1.67E-02
4 0.32 0.008 0.012 3.11E-04 4.66E-04 5.28E-04 4.04E-04 5.56E-02 6.29E-02 4.84E-02
14 1.1 g 0.029 0.012 3.16E-04 2.30E-03 2.48E-03 2.12E-03 7.95E-02 8.57E-02 7.32E-02
60 4.6 0.116 0.012 3.04E-04 1.02E-02 1.13E-02 9.05E-03 8.73E-02 9.69E-02 7.78E-02
170 11.6 0.289 0.012 2.99E-04 1.27E-02 1.54E-02 9.94E-03 4.38E-02 5.33E-02 3.44E-02
520 30.9 0.720 0.012 2.80E-04 1.70E-02 1.99E-02 1.41E-02 2.36E-02 2.77E-02 1.96E-02
Duodenum 
Fraction of 
Body 
Weightb
Mean 
Dose 
Fraction 
Absorbede
95% UCL 
Dose 
Fraction 
Absorbed
95% LCL 
Dose 
Fraction 
Absorbed
aDoses and total daily doses from Table 1.
bTissue-speciﬁc fractions of body weight from Table 4 of Kirman et al. (2012).
cCalculated as fraction of body weight  body weight from Table 1.
dCalculated as tissue weight  tissue concentration (mean, 95% UCL, or 95% LCL) from Table 1; tissue concentrations associated with bold italicized values were compared to
each other and are statistically signiﬁcantly different by unpaired t-test (p < 0.001).
eCorrected for background concentrations in controls at 0 dose.
fCorresponds to the federal MCL of 0.1 mg Cr/L.
gCorresponds to the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day).
Table 4
Absorbed dose fraction estimates for the mouse jejunum.
Drinking Water 
Concentration Dosea
Total Daily 
Dose
Jejunum 
Weightc
Jejunum 
Total Crd
95% UCL 
Jejunum 
Total Cr
95% LCL 
Jejunum 
Total Cr 
(mg SDD/L)  (mg Cr/kg-
day)
 (mg Cr/day) (kg) (mg) (mg) (mg)
0 0 0 0.021 5.42E-04 2.49E-05 4.25E-05 7.39E-06
0.3 f 0.024 0.001 0.021 5.54E-04 1.88E-05 2.74E-05 1.03E-05 0 0 4.58E-03
4 0.32 0.008 0.021 5.44E-04 5.98E-05 8.06E-05 3.90E-05 4.21E-03 4.61E-03 3.82E-03
14 1.1 g 0.029 0.021 5.52E-04 1.82E-04 3.00E-04 6.44E-05 5.44E-03 8.91E-03 1.97E-03
60 4.6 0.116 0.021 5.31E-04 2.50E-03 3.79E-03 1.21E-03 2.12E-02 3.22E-02 1.03E-02
170 11.6 0.289 0.021 5.23E-04 1.13E-02 1.70E-02 5.60E-03 3.90E-02 5.87E-02 1.94E-02
520 30.9 0.720 0.021 4.89E-04 6.80E-03 9.29E-03 4.32E-03 9.41E-03 1.28E-02 5.99E-03
Jejunum 
Fraction of 
Body 
Weightb
Mean 
Dose 
Fraction 
Absorbede
95% UCL 
Dose 
Fraction 
Absorbed
95% LCL 
Dose 
Fraction 
Absorbed
aDoses and total daily doses from Table 1.
bTissue-speciﬁc fractions of body weight from Table 4 of Kirman et al. (2012).
cCalculated as fraction of body weight  body weight from Table 1.
dCalculated as tissue weight  tissue concentration (mean, 95% UCL, or 95% LCL) from Table 1; tissue concentrations associated with bold italicized values were compared to
each other and practically achieved a statistically signiﬁcant difference by unpaired t-test (p = 0.052).
eCorrected for background concentrations in controls at 0 dose, negative corrected values set to zero.
fCorresponds to the federal MCL of 0.1 mg Cr/L.
gCorresponds to the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day).
Table 5
Absorbed dose fraction estimates for the mouse ileum.
Drinking Water 
Concentration Dosea
Total Daily 
Dose
Ileum 
Weightc
Ileum 
Total Crd
95% UCL 
Ileum 
Total Cr
95% LCL 
Ileum 
Total Cr 
(mg SDD/L)  (mg Cr/kg-
day)
 (mg Cr/day) (kg) (mg) (mg) (mg)
0 0 0 0.0063 1.63E-04 3.25E-06 4.33E-06 2.17E-06
0.3 f 0.024 0.001 0.0063 1.66E-04 2.33E-06 2.33E-06 2.33E-06 0 0 2.43E-04
4 0.32 0.008 0.0063 1.63E-04 6.85E-06 1.08E-05 2.89E-06 4.35E-04 7.83E-04 8.65E-05
14 1.1 g 0.029 0.0063 1.66E-04 2.15E-05 2.48E-05 1.82E-05 6.32E-04 7.09E-04 5.56E-04
60 4.6 0.116 0.0063 1.59E-04 1.47E-04 2.64E-04 2.94E-05 1.23E-03 2.23E-03 2.34E-04
170 11.6 0.289 0.0063 1.57E-04 2.82E-04 4.09E-04 1.55E-04 9.66E-04 1.40E-03 5.31E-04
520 30.9 0.720 0.0063 1.47E-04 3.38E-04 4.30E-04 2.45E-04 4.64E-04 5.92E-04 3.37E-04
95% LCL 
Dose 
Fraction 
Absorbed
Ileum 
Fraction of 
Body 
Weightb
Mean 
Dose 
Fraction 
Absorbede
95% UCL 
Dose 
Fraction 
Absorbed
aDoses and total daily doses from Table 1.
bTissue-speciﬁc fractions of body weight from Table 4 of Kirman et al. (2012).
cCalculated as fraction of body weight  body weight from Table 1.
dCalculated as tissue weight  tissue concentration (mean, 95% UCL, or 95% LCL) from Table 1; tissue concentrations associated with bold italicized values were compared to
each other and are statistically signiﬁcantly different by unpaired t-test (p < 0.001).
eCorrected for background concentrations in controls at 0 dose, negative corrected values set to zero.
fCorresponds to the federal MCL of 0.1 mg Cr/L.
gCorresponds to the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day).
J. Haney Jr. / Regulatory Toxicology and Pharmacology 71 (2015) 93–100 95
96 J. Haney Jr. / Regulatory Toxicology and Pharmacology 71 (2015) 93–1002. Materials and methods
Tissue concentration data reported by Kirman et al. (2012) were
evaluated for this study. Kirman et al. report total and added chro-
mium (Cr) mouse target tissue (i.e., duodenum, jejunum, ileum)
concentrations that were collected to support the rodent PBTK
model (Tables 1 and 2). In addition to drinking water concentra-
tions used in the CrVI rodent drinking water study (NTP, 2008),
these data include two lower water concentrations (0.3 and 4 mg
sodium dichromate dehydrate (SDD)/L) and their corresponding
daily Cr doses. The lowest water concentration tested for Kirman
et al. corresponds to the federal maximum contaminant level for
chromium (MCL of 0.1 mg Cr/L), making these data more relevant
to possible environmental exposures than those from the NTP
study (although still at concentrations and doses much higher than
typical human exposures). Additionally, the current study uses
USEPA benchmark dose (BMD) software (version 2.5) to model
tissue concentration versus dose so that absorbed dose fractionsTable 6
Duodenum best-ﬁtting model tissue concentration prediction.
Hill Model (non-constant variance)
equation:
Y [tissue conc. in mg/kg
at dose] = intercept + v * dose^n/
(k^n + dose^n)
Parameters Inputs
Dose (mg/kg-day)a 0.008
Intercept 0.018
v 62.397
n 1.406
k 4.638
Solve for Y [tissue conc. in mg/kg at dose] 0.026
a Corresponds to one-third the mouse dose at the federal MCL.
Fig. 1. Mouse duodenum tissue concentration versus daily dose.
Table 7
Absorbed dose fraction estimates based on modeled tissue concentrations for the mouse
Drinking water concentration
(mg SDD/L)
Dosea
(mg Cr/kg-day)
Total daily dose
(mg Cr/day)
Duod
(mg
1/3 the MCL 0.008 2.11E04 0.026
1/2 the MCL 0.012 3.16E04 0.032
a Doses and total daily doses at 1/3 and 1/2 the MCL were calculated based on these
b Tissue concentrations at 1/3 and 1/2 the MCL based on the BMD modeling equation
c Calculated as predicted tissue concentration x tissue weight at the MCL of 0.1 mg C
d Corrected for the mean background duodenum tissue concentration in controls at 0corresponding to doses up to three times lower than the lowest
tested for Kirman et al. (2012) can be calculated.
The dose fractions absorbed into target tissues were calculated
using the target tissue concentration data and tissue weights to
ﬁrst calculate the total amount of Cr in the target tissue (i.e., tissue
concentration in mg Cr/kg tissue  tissue weight in kg = total mg
Cr in tissue), and then dividing by the total daily dose (mg Cr/
day, although use of cumulative dose would not change the
relative differences in dose fraction absorbed at various doses).
However, the target tissue concentration data presented in Table 1
for CrVI exposed mice are not corrected for the background Cr
tissue levels present in control mice not exposed to CrVI. Thus,
when calculating the CrVI dose fractions absorbed by these tissues
(presented later in Tables 3–5), the background total Cr in a tissue
was subtracted from that in exposed mice to represent only the
additional Cr present in tissues due to the CrVI exposure (e.g., total
Cr in a tissue due to CrVI exposure = total tissue Cr  background
total tissue Cr in control mice). While this correction is not needed
for the added Cr (over background) tissue concentration data
presented in Table 2, data from both tables were used in order to
evaluate and ensure consistency of results. The same process was
used for 95% upper conﬁdence limit (UCL) and 95% lower conﬁ-
dence limit (LCL) estimates. Accordingly, the dose fraction
absorbed by a target tissue (i.e., duodenum, jejunum, ileum) at a
given dose is calculated as follows:
Dose FractionAbsorbed¼Total AddedCr in Target Tissue=CrDose
Absorbed dose fraction calculations based on the reported tis-
sue concentration means, 95% UCL and 95% LCL estimates, and
modeled tissue concentrations at even lower doses can be used
to derive an adjustment factor for the draft SFo (0.5 per mg/kg-day;
USEPA, 2010) to make it more predictive of excess risk at low
doses, that is, doses lower than the point-of-departure (POD) used
to calculate the SFo. More speciﬁcally, an evaluation of these
tissue concentration data (based on both the empirical data
collected and modeling the data) utilizing relatively straightforward
calculations is used in this study to determine the factors by which
the fractions of dose absorbed by target tissues decrease at lower,
more environmentally-relevant doses compared to the POD made
basis for the draft SFo (BMDL10 values of 1–1.1 mg/kg-day). These
factors account for dose-dependent changes in the dose fraction
absorbed that are important to adjust for when the SFo is
calculated based on a dose where an appreciably higher fraction
is absorbed compared to the fractions absorbed at lower doses
where the SFo will be used to estimate risk:
Adjustment Factor ¼ DFAPOD=DFAERD
where:
DFAPOD =
P
dose fractions absorbed by target tissues at the SFo
POD; and DFAERD =
P
dose fractions absorbed by target tissues at a
lower, more environmentally-relevant dose where the SFo will be
used to estimate risk.duodenum.
enum tissue concentrationb
Cr/kg tissue)
Duodenum total Crc
(mg)
Mean dose fraction
absorbedd
8.19E06 1.38E02
1.02E05 1.55E02
fractions  the doses at the MCL of 0.1 mg Cr/L (0.3 mg SDD/L) from Table 1.
in Table 6.
r/L (0.3 mg SDD/L) from Table 1.
dose (0.017 mg Cr/kg tissue or total tissue Cr of 5.26E06 mg) from Table 1.
Fig. 2. Mouse jejunum tissue concentration versus daily dose.
Fig. 3. Mouse ileum tissue concentration versus daily dose.
Table 8
Absorbed dose fraction estimates based on modeled tissue concentrations for the m
Drinking water
concentration
(mg SDD/L)
Dosea
(mg Cr/kg-day)
Total daily
dose
(mg Cr/day)
Jejunum tissue
concentrationb
(mg Cr/kg tissue)
1/3 the MCL 0.008 2.11E04 0.0434
1/2 the MCL 0.012 3.16E04 0.0435
a Doses and total daily doses at 1/3 and 1/2 the MCL were calculated based on
b Jejunum and ileum tissue concentrations at 1/3 and 1/2 the MCL based on the
c Calculated as predicted tissue concentration  tissue weight at the MCL of 0.1
d BMD model-predicted jejunum and ileum tissue concentrations at 1/3 and 1
0.020 mg Cr/kg tissue, respectively, so to correct for background tissue concentrat
were set to zero.
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predictive of risk a dose lower and more environmentally-relevant
than those used in NTP (2008):
Adjusted SFo ¼ SFo=Adjustment Factor
Lastly, examples of adjusted USEPA draft SFo values for CrVI are
used to calculate excess risk at the federal MCL (0.1 mg/L) and a
high but environmentally-relevant drinking water concentration
(i.e., the maximum reported city drinking water concentration in
EWG, 2010).ouse j
Jej
tot
Cr
2.4
2.4
these
BMD
mg C
/2 the
ions th3. Results and discussion
There are dose-dependent differences in the dose fraction
absorbed by target tissues (Tables 3–5) based on analysis of the tis-
sue concentration data collected to support the rodent PBTK model
(Kirman et al., 2012). As drinking water concentrations and associ-
ated doses increase from 0 to 60 mg SDD/L, the mean dose frac-
tions absorbed also increase. This is true for all three target
tissues, including the duodenum as the most carcinogenesis-
responsive tissue (Table 3) and the jejunum (Table 4) as the sec-
ondary contributor to the draft SFo.
The dose fractions absorbed based on 95% UCL tissue concentra-
tions also generally increase with dose as drinking water concen-
trations increase from 0 to 60 mg SDD/L. Based on 95% LCL tissue
concentrations, the dose fractions absorbed by the duodenum
(Table 3) also increase with dose over this drinking water concen-
tration range (95% LCL results for the jejunum and ileum were
more mixed).
While the dose fractions absorbed by target tissues increase
with dose as drinking water concentrations increase from 0 to
60 mg SDD/L (Tables 3–5), it is apparent at the highest and least
environmentally-relevant drinking water concentration doses
(e.g., the two highest doses for the duodenum and ileum and the
highest dose for the jejunum) that these tissues are unable to con-
tinue to absorb an ever-increasing fraction of the dose (although
measured tissue concentrations are higher at these extremely high
doses). Kirman et al. (2012) note that there is lower fractional
absorption at the higher doses (>10 mg/kg-day at the two highest
doses) where CrVI absorption is saturated, perhaps due to a toxic
response (e.g., villi toxicity affecting transporter-mediated absorp-
tion and greater cell sloughing). However, as these higher doses are
entirely irrelevant to environmental doses, this animal study high-
dose phenomenon (CrVI absorption saturation at exceedingly high
doses) does not detract from the signiﬁcance of the results pre-
sented in the current paper for lower study doses that are still
orders of magnitude higher than environmental exposures. For
example, while the lowest water concentration tested in Kirman
et al. of 0.3 mg SDD/L (0.1 mg Cr/L) is about 50 times less than
the lowest concentration of 14.3 mg SDD/L tested in NTP (2008),
it is still 555 times higher than the 35-city drinking water geomet-
ric mean (GM) and about 8 times higher than the city with the
highest drinking water concentration (EWG, 2010).
In regard to more tissue- and dose-speciﬁc results, the duode-
num and jejunum are the target tissues where the vast majority
of adenomas/carcinomas were found in NTP (2008). Table 3 shows
that the dose fraction absorbed by the mouse duodenum is approx-
imately four times higher at the POD used for the draft SFo deriva-
tion than at the federal MCL (note that the duodenum tissue
concentrations associated with these doses are statistically signif-
icantly different than each other; p < 0.001). This is signiﬁcant
given that the duodenum was the target tissue where most ofejunum and ileum.
unum
al
c (mg)
Mean dose
fraction
absorbedd
Ileum tissue
concentrationb
(mg Cr/kg tissue)
Ileum
total Crc
(mg)
Mean dose
fraction
absorbedd
06E05 0 0.0164 2.73E06 0
10E05 0 0.0165 2.74E06 0
fractions  the doses at the MCL of 0.1 mg Cr/L (0.3 mg SDD/L) from Table 1.
modeling equations (not shown) from best-ﬁtting models.
r/L (0.3 mg SDD/L) from Table 1.
MCL were just below the control (0 dose) background tissue levels of 0.046 and
e dose fraction absorbed values at 1/3 and 1/2 the MCL for the jejunum and ileum
Table 9
Absorbed dose fraction estimates for the three mouse target tissues and SFo adjustment factors.
Drinking
water
concentration
(mg SDD/L)
Dosea
(mg
Cr/kg-
day)
Total
daily
dose (mg
Cr/day)
Duodenum
mean dose
fraction
absorbedb
Duodenum
95% UCL dose
fraction
absorbed
Duodenum
95% LCL dose
fraction
absorbed
Jejunum
mean dose
fraction
absorbedb
Jejunum 95%
UCL dose
fraction
absorbed
Jejunum
95% LCL
dose
fraction
absorbed
Ileum
mean dose
fraction
absorbedb
Ileum 95%
UCL dose
fraction
absorbed
Ile 95%
LC ose
fra ion
ab rbed
3-Tissue
mean dose
fraction
absorbedc
3-Tissue 95%
UCL dose
fraction
absorbed
3-Tissue
95% LCL
dose
fraction
absorbed
1/3 MCL 0.008 2.11E04 1.38E02 0 0 1.38E02
1/2 MCL 0.012 3.16E04 1.55E02 0 0 1.55E02
0.3d 0.024 6.34E04 1.97E02 2.27E02 1.67E02 0 0 4.58E03 0 0 2.4 E04 1.97E02 2.27E02 2.15E02
4 0.32 8.29E03 5.56E02 6.29E02 4.84E02 4.21E03 4.61E03 3.82E03 4.35E04 7.83E04 8.6 E05 6.03E02 6.83E02 5.23E02
14 1.1e 2.89E02 7.95E02 8.57E02 7.32E02 5.44E03 8.91E03 1.97E03 6.32E04 7.09E04 5.5 E04 8.55E02 9.53E02 7.58E02
60 4.6 1.16E01 8.73E02 9.69E02 7.78E02 2.12E02 3.22E02 1.03E02 1.23E03 2.23E03 2.3 E04 1.10E01 1.31E01 8.83E02
170 11.6 2.89E01 4.38E02 5.33E02 3.44E02 3.90E02 5.87E02 1.94E02 9.66E04 1.40E03 5.3 E04 8.38E02 1.13E01 5.43E02
520 30.9 7.20E01 2.36E02 2.77E02 1.96E02 9.41E03 1.28E02 5.99E03 4.64E04 5.92E04 3.3 E04 3.35E02 4.11E02 2.59E02
SFo adjustment factorsf:
Based on
lowest
dose (at
MCL)
4.3 4.2 3.5
Based on
modeling
at 1/3 MCL
6.2
a Doses and total daily doses from Table 1, except doses at 1/3 and 1/2 the MCL were calculated based on these fractions  the doses at the MCL of 0.1 mg Cr/L (0.3 g SDD/L).
b Mean and 95% UCL/LCL values from Tables 3–5 for doses tested in Kirman et al. (2012), and Tables 7 and 8 for mean dose fraction absorbed estimates at 1/3 and 1 the MCL.
c Sum of dose fractions absorbed (corrected for background tissue concentrations) for all three tissue mean, 95% UCL, or 95% LCL values.
d Corresponds to the federal MCL of 0.1 mg Cr/L.
e Corresponds to the POD used for the draft SFo (BMDL10 values of 1.0–1.2 mg/kg-day).
f Calculated as dose fraction absorbed at draft SFo POD/fraction absorbed at the MCL or 1/3 the MCL.
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Fig. 4. Dose fraction absorbed versus dose.
J. Haney Jr. / Regulatory Toxicology and Pharmacology 71 (2015) 93–100 99the adenomas/carcinomas occurred in NTP (2008) and therefore
was the principal contributor to the draft SFo. Similar to Table 3,
Tables 4 and 5 show that the dose fractions absorbed into the
mouse jejunum and ileum are higher at the POD used for the draft
SFo derivation than at the federal MCL. This is of particular impor-
tance for the jejunum since this target tissue was a secondary con-
tributor to the mouse adenomas/carcinomas observed in NTP
(2008) and therefore contributed secondarily to the draft SFo.
Not surprisingly, since the calculations in Tables 3–5 account for
background tissue concentrations, essentially identical results
were obtained using the added Cr tissue data provided in Table 2
(calculations not shown). Consequently, analyses based on data
from Table 2 are not discussed further.
Greater differences in the dose fraction absorbed were found
(compared to the dose fraction absorbed at the draft SFo POD)
when duodenum tissue concentrations were modeled as a func-
tion of dose (BMD software version 2.5) in order to estimate
absorbed dose fractions at one-half and one-third of the MCL.
Fig. 1 shows good model ﬁt (goodness-of-ﬁt was evaluated by
visual inspection with scaled residuals <|2| and a goodness-of-ﬁt
p value >0.1).
The equation and parameter estimates for this response func-
tion (provided by BMD software) were then used to calculate the
estimated mean duodenum tissue concentrations at one-half and
one-third of the MCL (3.2E02 and 2.6E02 mg/kg, respectively)
since the MCL was the lowest water concentration for which data
are provided in Kirman et al. (2012), drinking water concentrations
are typically signiﬁcantly below the MCL (e.g., EWG, 2010), and
BMD modeling is generally not used to extrapolate to doses far
below the experimental range (USEPA, 1995). For example, Table 6
provides the relevant inputs for the duodenum tissue concentra-
tion calculation at one-third of the federal MCL.
As in Table 3, these tissue concentrations and the total daily
doses that would have been associated with one-half and one-third
of the MCL (3.2E04 and 2.1E04 mg Cr/day, respectively) were
used to estimate the dose fractions absorbed at these lower drink-
ing water concentrations. The calculated absorbed dose fractions
were approximately 1.6E02 and 1.4E02, respectively (Table 7).
Based on these results, the calculated dose fraction absorbed by
the mouse duodenum is approximately six times higher at the POD
used for the draft SFo derivation than at one-third of the federal
MCL. This is signiﬁcant given that most cancers occurred in this tis-
sue in NTP (2008) and that typical drinking water concentrations
are still almost 200 times lower than one-third the MCL
(0.033 mg/L/35-city drinking water GM of 0.00018 mg/L  183).
Predictions by response function equations from good-ﬁtting
BMD models (Figs. 2 and 3) for the jejunum (high dose dropped)
and ileum at even one-half the MCL (4.3E02 and 1.6E02mg/kg,
respectively) were slightly lower than mean background levels
for those tissues (calculations not shown). Therefore, to account
for background tissue concentrations, the dose fractions absorbed
by these tissues (corrected for background) were set to zero at
one-third and one-half of the MCL (Table 8).
Finally, in Table 9 absorbed doses by all three target tissues
(from Tables 3–5, 7 and 8) are used to calculate overall SFo adjust-
ment factors which account for differences in the dose fraction
absorbed at the POD made basis for the draft SFo versus the
fractions absorbed at lower, more environmentally-relevant doses
(i.e., 1/3 the MCL and the lowest dose tested for Kirman et al.,
2012).
The results in Table 9 show that the dose fraction absorbed by
target tissues at the POD dose used in USEPA (2010) for the draft
SFo calculation (BMDL10 values of 1–1.1 mg/kg-day) is approxi-
mately four times higher than that at the MCL and about six times
higher than that predicted at one-third of the MCL. Fig. 4 shows
dose fraction absorbed versus dose for the lower drinking waterconcentrations of 0.3–60 mg SDD/L, which are closer to (although
still signiﬁcantly above) environmentally-relevant drinking water
concentrations.
Consideration of the shape of the curve in Fig. 4 suggests that
using proportionality/linearity to estimate the expected dose frac-
tion absorbed at truly low, environmentally-relevant water con-
centrations may be predictive. The 35-city drinking water GM
(0.00018 mg/L) is over 500 times lower than the MCL (0.1 mg/L),
the lowest water CrVI concentration tested in Kirman et al.
(2012) and shown in Fig. 4. An estimate of the dose fraction
absorbed at 0.00018 mg/L based on proportionality with the frac-
tion absorbed at the lowest water concentration tested (0.3 mg
SDD/L or 0.1 mg Cr/L) would be:
Dose Fraction AbsorbedðÞ=0:00018mgCr=L
¼ 1:97E 02=0:1mgCr=L
Dose Fraction AbsorbedðÞ ¼ ð1:97E 02=0:1mgCr=LÞ
 0:00018mgCr=L
Dose Fraction AbsorbedðÞ ¼ 3:55E 05
This estimate of the dose fraction which may be absorbed at the
35-city drinking water GM is over 2400 times lower than that
calculated (8.55E02 from Table 9) for the water concentration
and dose (1.1 mg Cr/kg-day at 14 mg SDD/L) corresponding to
the POD for the draft SFo (an adjustment factor of 2408). Even
for the city with the highest drinking water concentration
(0.0129 mg/L) reported in EWG (2010), the estimate of the dose
fraction absorbed (2.54E03; calculation not shown) is over 30
times lower than that calculated for the draft SFo POD (an adjust-
ment factor of 34).4. Conclusions
The above analyses show dose-dependent differences in the
dose fraction absorbed by target tissues. More speciﬁcally, the dose
fraction absorbed increases with dose from 0 to 60 mg SDD/L
(0–21mg Cr/L), which is up to 210 times the federal MCL (0.1 mg/L).
Additionally, compared to the POD dose used in USEPA (2010) for
the draft SFo calculation (BMDL10 values of 1–1.1 mg/kg-day),
analysis of the tissue concentration data collected (Table 9) indi-
cates that the fractions of dose absorbed into target tissues of the
mouse small intestine (duodenum, jejunum, ileum) are appreciably
lower at lower doses. This may be due to dose-dependent changes
100 J. Haney Jr. / Regulatory Toxicology and Pharmacology 71 (2015) 93–100in the competing rates of reduction/detoxiﬁcation prior to CrVI
absorption by target tissues. Based on both the absorbed dose
fractions calculated using measured target tissue concentration
data and the absorbed fractions predicted at doses lower than those
tested, it is further concluded that the magnitude of risk over-
estimation by the draft SFo (0.5 per mg/kg-day) increases as it is
used to estimate excess risk at progressively lower, more environ-
mentally-relevant water concentrations where the dose fractions
absorbed become progressively lower.
To be more predictive of risk, the draft SFo for CrVI should be
adjusted by dose-speciﬁc adjustment factors (which vary) to
account for the lower dose fractions absorbed by target tissues at
lower, more environmentally-relevant water concentrations and
doses as compared to the dose fraction absorbed at the water
concentration and dose (1.1 mg Cr/kg-day at 14 mg SDD/L) corre-
sponding to the POD for the draft SFo (BMDL10 values of
1–1.1 mg/kg-day). For example, the 4-fold difference between the
dose fraction absorbed at the MCL versus that at the water concen-
tration corresponding to the draft SFo POD (see Table 9) indicates
that the draft SFo over-predicts cancer risk by around four times
even at the MCL (0.1 mg/L), (note that when the mouse dose at
the MCL is converted to a human equivalent dose, the human dose
is that expected for humans at the MCL) which is over 500 times
higher than typical drinking water levels (e.g., 35-city GM of
0.00018 mg/L reported in EWG, 2010). Using this factor of 4 to
adjust the draft SFo for the estimation of risk at the approximate
human dose (2.9E03 mg/kg-day) associated with the MCL results
in an excess risk of about 3.6E04. However, even the one-third of
the MCL evaluated in this study is almost 200 times higher than
typical drinking water concentrations (e.g., GM of 0.00018 mg/L),
and the 6-fold difference between the dose fraction absorbed at
one-third of the MCL versus that at the draft SFo POD (see Table 9)
indicates that the draft SFo over-predicts cancer risk by around six
times even at this high, atypical drinking water concentration
(0.033 mg/L). In fact, the highest drinking water concentration
(0.0129 mg/L) reported in EWG (2010) is only about one-eighth
of the MCL. Perhaps even more pertinent to the propensity of the
draft SFo to over-estimate environmental risk, estimates of the
much lower dose fractions that may be absorbed at environmen-
tally-relevant concentrations (0.00018–0.0129 mg/L) suggest that
risk over-estimation by the draft SFo for drinking water concentra-
tions that humans are likely to be exposed to may very well span
orders of magnitude (tens to perhaps thousands). Furthermore,
based on alternative MOAs, the carcinogenic risk at low (i.e., envi-
ronmental) doses could be as low as zero (Thompson et al., 2013).
Considering that risk over-estimation by the draft SFo for envi-
ronmentally-relevant drinking water concentrations is likely to be
at least an order of magnitude and may span multiple orders of
magnitude, these analyses suggest the draft SFo be divided by a
dose-speciﬁc adjustment factor of at least an order of magnitude
(adjusted SFo of 60.05 per mg/kg-day) to be less over-predictive
of risk at human-relevant doses (e.g., 0.0129 mg/L). Use of an
example adjusted SFo to conservatively estimate risk at the
approximate human dose (3.7E04 mg/kg-day) corresponding to
the highest reported CrVI tap water concentration (0.0129 mg/L)
from EWG (2010) results in a high-end excess risk estimate no
greater than 1.9E05. This CrVI drinking water risk is well within
USEPA’s acceptable risk range (1E06–1E04).
Potential limitations of this study include the assumption that
90-day tissue concentration data (Kirman et al., 2012) are repre-
sentative of those for longer-term exposure (NTP, 2008) in a rela-
tive (not absolute) manner. That is, that the relative proportions
of the dose fractions absorbed at various doses do not change sig-
niﬁcantly with longer exposure. The lack of target tissue data at
truly environmentally-relevant drinking water concentrations
and doses and the use of modeling (i.e., BMD, proportionalitycalculations) to account for this is another limitation and/or uncer-
tainty associated with some analyses, although the information
available supports the approaches utilized. Although the relative
simplicity of the approach employed in the current study may be
viewed as a limitation compared to the more elegant PBTK models
that have been developed (Kirman et al., 2012, 2013), its straight-
forwardness and ease of understanding can also be viewed as
strengths. An assumption inherent in adjusting an SFo in this man-
ner based on dose fraction absorbed is that risk is proportional to
target tissue dose. However, the assumption that target tissue dose
is linearly related to risk is inherently part of the default linear
low-dose extrapolation method commonly used in regulatory risk
assessment and regarded as conservative (i.e., health protective, no
threshold is assumed). On the other hand, although the present
study assumes low-dose linearity of target tissue dose (not oral
dose) and risk (i.e., a mutagenic MOA), this paper should not be
viewed as an endorsement of it in the MOA debate, as this
approach may not be the best supported low-dose extrapolation
method for CrVI oral risk assessment (e.g., estimating risk at
environmental doses) based on the available information relevant
to the MOA for CrVI-induced oral carcinogenicity (e.g., Thompson
et al., 2011a, 2013). Performing a weight-of-evidence on the most
likely carcinogenic MOA, however, is beyond the scope of this
paper.
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